Antibody-nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants항체-나노바디 조합은 SARS-CoV-2에 대한 중화 활성을 증가시키고 나노바디 H11-H4는 알파, 카파 및 델타 변이체에 대해 효과적입니다.Article Published on 2022-06-112022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha antibodies antibody association Beta binding binding affinity combating Combination complex COVID-19 CR3022 delta variant Delta variants effective electrostatic interaction elicited experiment Gamma H11-H4 health system IMPROVE increase Interaction investigated Lambda llama molecular molecular dynamics Molecular dynamics simulation molecular dynamics simulations molecular mechanism molecular mechanisms nanobodies nanobody Neutralizing Neutralizing activity observation predict RBD recent Receptor binding domain reduce SARS-CoV-2 SARS-CoV-2 spike protein significantly Spike protein spread of COVID-19 the binding affinity the SARS-CoV-2 the spike protein Treatment Vaccine van der Waal variant variants of SARS-CoV-2 while [DOI] 10.1038/s41598-022-14263-1 PMC 바로가기 [Article Type] Article
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations류마티스성 근골격계 질환의 면역억제제 치료는 SARS-CoV-2 감염에 대한 체액 반응의 유발을 억제하지 않고 이펙터 면역 세포 집단을 보존합니다Article Published on 2022-06-102022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료법, [키워드] adaptive addition affected Analysis antibody Antibody Response Antibody responses Arthritis B lymphocytes biologic carried Cellular immune response COVID-19 CTLA4 disease disease-modifying anti-rheumatic drug Disease-modifying anti-rheumatic drugs Diseases DMARD drug effector elicit functional humoral Humoral and cellular immune responses immune immune cell populations immune response immune responses immune system immunological Immunosuppressant include individual Inflammatory Inflammatory arthritis inhibitor inhibitors life-threatening Musculoskeletal Neutralizing activity Pathologies Patient patients treated Population presenting provide RBD protein RBD proteins Re-infections response rheumatic musculoskeletal diseases. SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleocapsid sustained the antibody response TNF-α Treatment virus [DOI] 10.3389/fimmu.2022.873195 PMC 바로가기 [Article Type] Article
The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs다양한 SARS-CoV-2 변종 RBD 간의 교차 보호 면역 환경Article Published on 2022-06-102022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha antibody Antigen antigens Beta COVID-19 vaccine design cross-neutralization cross-neutralizing cross-protective cross-protective immunity Delta effective evaluated expressed IgG antibodies immune protection immunize Lambda landscape mice neutralization neutralization antibodies Neutralizing activity new SARS-CoV-2 omicron pentavalent pseudovirus pseudoviruses RBD RBD antigen RBD protein SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 variants the epidemic These data titers of IgG Vaccine vaccine strain Vaccines variant variants wild type [DOI] 10.3389/fimmu.2022.898520 PMC 바로가기 [Article Type] Article
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants조상 SARS-CoV-2, 베타, 델타 및 오미크론 변이체의 임상 분리주에 대한 회복기 및 백신 접종 혈청의 면역원성Article Published on 2022-06-102022-09-11 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] antibody Antibody titers Beta booster vaccination Canada CL3 clinical isolates convalescent convalescent individual convalescent individuals convalescent sera coronavirus coronavirus disease COVID-19 Delta delta variant demonstrated dose foundation Government immunogenicity individual induce initiative Innovation isolate long-term Major microneutralization Ministry of Agriculture Moderna multiple mutation multiple mutations neutralization Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody Neutralizing antibody titer omicron Omicron variant Pfizer raising receive recipient reduced Research SARS-CoV-2 Science sera significantly higher Spike protein the spike protein vaccinated individual vaccinated individuals Vaccine variant variants variants of concern VIDO virus VoC VOCs [DOI] 10.1016/j.medj.2022.04.002 PMC 바로가기 [Article Type] Article
Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine항중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 스파이크 단백질 항체 역가 및 BNT162b2 백신 접종 후 의료 종사자의 중화 활성과 관련된 요인Observational Study Published on 2022-06-102022-09-12 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] acute respiratory syndrome Adverse reaction age All participant Analysis anti-SARS-CoV-2 IgM antibody Antibody titer blood sample BNT162b2 vaccine chemiluminescent immunoassay conducted coronavirus Cutoff elevated Enrollment Factor female Fever first dose Fukushima healthcare worker hospital identify IgG IgG antibody IgG antibody titer IgM Immunoglobulin Immunoglobulin G immunosuppressive increase in individuals intake Japan joint lack Local medication N-protein Neutralizing activity Neutralizing antibody titer of BNT162b2 Pain participant Pfizer-BioNTech Prevent Protein response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose Sex significantly Spike protein the SARS-CoV-2 vaccination Vaccine vaccine doses was obtained were measured [DOI] 10.1371/journal.pone.0269917 PMC 바로가기 [Article Type] Observational Study
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccinesClinical and Translational Report Published on 2022-06-092022-10-04 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, [키워드] Abstract Affect Analysis Animal experiment antibody antibody cross-reactivity antibody response against association B.1.617.2 Booster vaccine breadth China circulating clinical evidence clinical observation Cohort Commission conducted confounders Context cost-efficient strategy COVID-19 vaccination COVID-19 vaccine Department development elicit Evidence finding foundation funding Health care worker healthcare worker Heterologous heterologous prime-boost heterologous vaccination heterologous vaccine homologous homologous or heterologous immune responses immunological analysis inactivated Influenza Innovation International Laboratory test mechanism Multivariable regression natural Neutralization antibody neutralization titer Neutralizing Neutralizing activity physician PNA Program protective immunity Pseudovirus neutralization assay recipient SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Science Serum Neutralization Shenzhen shown significantly lower subsequent suggested technology the United State the vaccine vaccination vaccination schedule Vaccine Vaccines variant variants veteran Virus neutralization Wuhan-Hu-1 [DOI] 10.1016/j.medj.2022.05.003 PMC 바로가기 [Article Type] Clinical and Translational Report
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2체외 세포 모델의 적절한 선택은 SARS-CoV-2에 대한 중화 항체 반응의 특성화에 영향을 미칩니다Article Published on 2022-06-072022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody Antibody Response BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine Calu Calu-3 cell line cell lines cellular characterization characterized choice collected correlation COVID-19 COVID-19 vaccine Cytopathic effect cytopathic effects demonstrated Entry mechanism entry mechanisms evaluated in vitro increasingly inhibitory activity lack mechanisms Model mRNA mRNA vaccine natural infection Neutralizing Neutralizing activity occur of BNT162b2 PCR pseudovirus pseudoviruses response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants SARS-CoV-2 viral Selection sera Single Cell subject Surrogates TMPRSS2 vaccine-induced antibodies vaccine-induced antibody variants Vero Vero E6 Viral viral entry viral entry pathway virus particles VOCs [DOI] 10.3390/v14061232 PMC 바로가기 [Article Type] Article
Efficacy of antibody response following the vaccination of SARS-CoV-2 infected and noninfected healthcare workers by two-dose inactive vaccine against COVID-19COVID-19에 대한 2회 접종 불활성 백신에 의한 SARS-CoV-2 감염 및 비감염 의료 종사자의 백신 접종 후 항체 반응의 효능Article Published on 2022-06-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgG antibodies anti-SARS-CoV-2 IgG antibody antibody Antibody Response Antibody responses appearance classical Comorbidities concerning coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection Day demographics detect Efficacy first dose healthcare worker IgG antibodies IgG level IgG levels immunogenicity Immunosuppression inactive individuals infected with SARS-CoV-2 Infection information investigated majority Neutralizing activity positive postvaccination produced rapid increase SARS-CoV-2 screened second dose second vaccination seropositive seropositive individual seropositive individuals Seropositivity significantly higher Sinovac subject subjects Support Symptoms titers vaccination Vaccine virus [DOI] 10.1002/jmv.27649 PMC 바로가기 [Article Type] Article
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infectionCOVID-19 재감염 이력이 있는 개인에서 SARS-CoV-2 mRNA-1273 백신 2회 접종 후 항체 반응Case Reports Published on 2022-06-012022-09-12 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] antibody Antibody Response antispike protein IgG antibody booster Case report COVID-19 COVID-19 infections dose evaluated first vaccination Generalizability IgG immunologic response Infection initial Japanese mRNA-1273 vaccine Neutralizing Neutralizing activity neutralizing antibody patients with COVID-19 Protein Re-infection remained SARS-CoV-2 second vaccination vaccination Vaccinations Vaccine [DOI] 10.1016/j.ijid.2022.03.017 PMC 바로가기 [Article Type] Case Reports
Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19-Convalescent Individuals순진한 개인과 COVID-19 회복기 개인에서 BNT162b2 백신 접종 후 8개월 후 SARS-CoV-2 변종에 대한 중화 반응Article Published on 2022-06-012022-09-11 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against BNT162b2 convalescent coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 declined detectable Evolution humoral individual individuals initial investigated Month naïve individuals Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody Pfizer proportion respiratory response SARS-CoV-2 SARS-CoV-2 delta severe acute respiratory syndrome Coronavirus vaccination Vaccine variant variant of concern variants [DOI] 10.1093/infdis/jiab634 PMC 바로가기 [Article Type] Article